Intra-Cellular Therapies' lumateperone shows significant efficacy in reducing schizophrenia relapse rates, with a 63% risk ...

Data presented at Psych Congress 2024 showed improvements in social functioning and quality of life over an eight-week ...

The study also included an 18-week open-label phase, during which patients with Schizophrenia were treated with Lumateperone 42 mg per day. The biopharmaceutical company found that the time to relapse ...

Bristol Myers Squibb's revenue was fueled by Growth Portfolio and Eliquis. Analysts anticipate an impact from Cobenfy and a ...

Intra-Cellular Therapies’ atypical antipsychotic medication Caplyta has been on a roll, delivering fast commercial growth and coming up triumphant in yet another late-stage trial. | Intra-Cellular ...

Some people who took a new schizophrenia drug for one year improved with only a few side effects, but many dropped out of the ...

044). Conversely, 6 taxa, such as rhodospirillaceae, defluviitaleaceae, and desulfovibrio, were protective against schizophrenia (OR: 0.88-0.94; P ≤.049). The findings may provide evidence for the ...

Schizophrenia significantly shortens life expectancy by an estimated 15 years with excess mortality arising from multiple ...

For the past 70 years, schizophrenia treatments all targeted the same chemical: dopamine. While that works for some, it ...

The distress from voices heard by schizophrenia patients were lessened when treated using digital avatars, new study showed.

Leal Therapeutics has secured yet another multi-million financing deal as the Worcester-based biotechnology startup has ...

Art therapy can help individuals express thoughts and feelings without relying solely on words, providing a valuable outlet ...